miR-657 Targets SRCIN1 via the Slug Pathway to Promote NSCLC Tumor Growth and EMT Induction

Figure 4

miR-657 directly targets SRCIN1. (a) SRCIN1 mRNA levels in NSCLC tumors and normal tissues were measured through qPCR (). (b) IHC staining was employed to assess SRCIN1 expression in 96 NSCLC patient tumor and healthy control tissue samples, with representative images being shown (×200, scale bar 100 μm). (c) SRCIN1 and miR-657 expression levels were negatively correlated. (d) SRCIN1 levels were measured in different cell lines. (e) SRCIN1 and miR-657 expression levels were negatively correlated in different cell lines. (f) SRCIN1 levels were measured in the indicated NSCLC cell lines following miR-657 mimic, inhibitor, or corresponding NC construct transfection. (g) SRCIN1 protein levels were assessed in NSCLC cell transfected as indicated. (h) SRCIN1 and miR-657 sequence complementarity. (i) Luciferase activity levels were appraised in 293T cells after miR-NC/miR-657 mimic or SRCIN1-WT/SRCIN1-MT cotransfection. (j) RIP assessments were employed to appraise the ability of miR-657 and SRCIN1 to interact in A549 cells. (k) RNA pull-down results showed that miR-657 could band with SRCIN1 in A549 cell lines. Data are . and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)